UB Paderborn / Katalog / Suche / in CDI

Periostin‐ and podoplanin‐positive cancer‐associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenocarcinoma

The Journal of pathology, 2022-12, Vol.258 (4), p.408-425

2022

Volltextzugriff (PDF)

Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition

Clinical cancer research, 2016-05, Vol.22 (10), p.2470-2481

2016

Volltextzugriff (PDF)

Unraveling galectin-1 as a novel therapeutic target for cancer

Cancer treatment reviews, 2014-03, Vol.40 (2), p.307-319

2014

Volltextzugriff (PDF)

Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy

Oral oncology, 2019-01, Vol.88, p.29-38

2019

Volltextzugriff (PDF)

Antitumor Agent Calixarene 0118 Targets Human Galectin-1 as an Allosteric Inhibitor of Carbohydrate Binding

Journal of medicinal chemistry, 2012-06, Vol.55 (11), p.5121-5129

2012

Volltextzugriff (PDF)

Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK‐8628 in malignant pleural mesothelioma xenografts

International journal of cancer, 2017-01, Vol.140 (1), p.197-207

2017

Volltextzugriff (PDF)

Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells

Cancer research (Chicago, Ill.), 2009-05, Vol.69 (10), p.4260-4269

2009

Volltextzugriff (PDF)

Abstract 3684: Basal Notch1 and Notch4 activation as potential markers of aggressiveness and sensitivity to Notch inhibition in human cancer cell lines

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.3684-3684

2020

Volltextzugriff (PDF)

Abstract 5103: Bidirectional EMT-dependent modulation of cancer cell and M1/M2 macrophage differentiation

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5103-5103

2020

Volltextzugriff (PDF)

OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis

European journal of cancer (1990), 2014-09, Vol.50 (14), p.2463-2477

2014

Volltextzugriff (PDF)

Abstract 859: Basal Notch4 activation is a druggable marker of aggressiveness in a panel of human cancer cell lines

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.859-859

2019

Volltextzugriff (PDF)

Abstract 1080: Link between M1/M2 human macrophages and epithelial-mesenchymal status in head and neck cancer cell lines

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.1080-1080

2019

Volltextzugriff (PDF)

Periostin‐ and podoplanin‐positive cancer‐associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenocarcinoma

The Journal of pathology, 2022-12, Vol.258 (4), p.408-425

2022

Volltextzugriff (PDF)

Abstract 2501: Involvement of Notch signaling pathway in a panel of human cancer cell lines

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.2501-2501

2018

Volltextzugriff (PDF)

Microbiome and pancreatic ductal adenocarcinoma

Clinics and research in hepatology and gastroenterology, 2021-03, Vol.45 (2), p.101589, Article 101589

2021

Volltextzugriff (PDF)

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus

Oncotarget, 2017-01, Vol.8 (5), p.7598-7613

2017

Volltextzugriff (PDF)

OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations

Oncotarget, 2016-12, Vol.7 (51), p.84675-84687

2016

Volltextzugriff (PDF)

Abstract 2944: TGF-β inhibitor galunisertib combined with antiangiogenic therapies showed antitumor effects in vitro and in vivo in hepatocellular carcinoma (HCC)

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.2944-2944

2018

Volltextzugriff (PDF)

Abstract 5529: In vitro evaluation of OTX015, a novel pan-BET-bromodomain (BET-BRD) inhibitor, as single agent and in combination with standard chemotherapy drugs in human leukemic cell lines

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.5529-5529

2014

Volltextzugriff (PDF)

Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models

Leukemia & lymphoma, 2019-10, Vol.60 (12), p.3067-3070

2019

Volltextzugriff (PDF)

Abstract 3527: OTX015, a novel BET-bromodomain (BET-BRD) inhibitor, displays antitumoral effects in orthotopic and heterotopic models of human glioblastoma

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.3527-3527

2015

Volltextzugriff (PDF)

Abstract 3530: Gene expression profile of OTX015, a BET bromodomain inhibitor, in preclinical models of non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) models

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.3530-3530

2015

Volltextzugriff (PDF)

Preclinical Evaluation of the BET-Bromodomain (BET-BRD) Inhibitor OTX015 in Leukemia Cell Lines Harboring the JAK2 V617F Mutation

Blood, 2014-12, Vol.124 (21), p.873-873

2014

Volltextzugriff (PDF)

OTX015 (MK-8628), a novel BET inhibitor, displays in vitroand in vivo antitumor effects alone and in combination withconventional therapies in glioblastoma models

International journal of cancer, 2016, Vol.139 (9), p.2047-2055

2016

Volltextzugriff (PDF)

Abstract 3526: OTX015 effects in triple-negative breast cancer (TNBC) models are independent of hypoxia conditions and synergistic with other anticancer agents

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.3526-3526

2015

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Periostin‐ and podoplanin‐positive cancer‐associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenocarcinoma

Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition

Unraveling galectin-1 as a novel therapeutic target for cancer

Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy

Antitumor Agent Calixarene 0118 Targets Human Galectin-1 as an Allosteric Inhibitor of Carbohydrate Binding

Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK‐8628 in malignant pleural mesothelioma xenografts

Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells

Abstract 3684: Basal Notch1 and Notch4 activation as potential markers of aggressiveness and sensitivity to Notch inhibition in human cancer cell lines

Abstract 5103: Bidirectional EMT-dependent modulation of cancer cell and M1/M2 macrophage differentiation

OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis

Abstract 859: Basal Notch4 activation is a druggable marker of aggressiveness in a panel of human cancer cell lines

Abstract 1080: Link between M1/M2 human macrophages and epithelial-mesenchymal status in head and neck cancer cell lines

Periostin‐ and podoplanin‐positive cancer‐associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenocarcinoma

Abstract 2501: Involvement of Notch signaling pathway in a panel of human cancer cell lines

Microbiome and pancreatic ductal adenocarcinoma

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus

OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations

Abstract 2944: TGF-β inhibitor galunisertib combined with antiangiogenic therapies showed antitumor effects in vitro and in vivo in hepatocellular carcinoma (HCC)

Abstract 5529: In vitro evaluation of OTX015, a novel pan-BET-bromodomain (BET-BRD) inhibitor, as single agent and in combination with standard chemotherapy drugs in human leukemic cell lines

Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models

Abstract 3527: OTX015, a novel BET-bromodomain (BET-BRD) inhibitor, displays antitumoral effects in orthotopic and heterotopic models of human glioblastoma

Abstract 3530: Gene expression profile of OTX015, a BET bromodomain inhibitor, in preclinical models of non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) models

Preclinical Evaluation of the BET-Bromodomain (BET-BRD) Inhibitor OTX015 in Leukemia Cell Lines Harboring the JAK2 V617F Mutation

OTX015 (MK-8628), a novel BET inhibitor, displays in vitroand in vivo antitumor effects alone and in combination withconventional therapies in glioblastoma models

Abstract 3526: OTX015 effects in triple-negative breast cancer (TNBC) models are independent of hypoxia conditions and synergistic with other anticancer agents

Suchergebnisse filtern